檢索結果 - Siddhartha Mitra

  • Showing 1 - 15 results of 15
Refine Results
  1. 1
    The Ubiquitin-Proteasome Pathway in Huntington's Disease

    The Ubiquitin-Proteasome Pathway in Huntington's Disease 由 Siddhartha Mitra, Steven Finkbeiner

    出版 2008
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    Single Neuron Ubiquitin-Proteasome Dynamics Accompanying Inclusion Body Formation in Huntington Disease

    Single Neuron Ubiquitin-Proteasome Dynamics Accompanying Inclusion Body Formation in Huntington Disease 由 Siddhartha Mitra, Andrey S. Tsvetkov, Steven Finkbeiner

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Protein turnover and inclusion body formation

    Protein turnover and inclusion body formation 由 Siddhartha Mitra, Andrey S. Tsvetkov, Steven Finkbeiner

    出版 2009
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Heterogeneous reallocation of presynaptic efficacy in recurrent excitatory circuits adapting to inactivity

    Heterogeneous reallocation of presynaptic efficacy in recurrent excitatory circuits adapting to inactivity 由 Ananya Mitra, Siddhartha Mitra, Richard W. Tsien

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

    Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death 由 Montserrat Arrasate, Siddhartha Mitra, Erik S. Schweitzer, Mark R. Segal, Steven Finkbeiner

    出版 2004
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Quantitative Relationships between Huntingtin Levels, Polyglutamine Length, Inclusion Body Formation, and Neuronal Death Provide Novel Insight into Huntington's Disease Molecular Pathogenesis

    Quantitative Relationships between Huntingtin Levels, Polyglutamine Length, Inclusion Body Formation, and Neuronal Death Provide Novel Insight into Huntington's Disease Molecular P... 由 Jason Miller, Montserrat Arrasate, Benjamin A. Shaby, Siddhartha Mitra, Eliezer Masliah, Steven Finkbeiner

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma

    Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma 由 Ajay K. Gopal, Michelle A. Fanale, Craig H. Moskowitz, Andrei R. Shustov, Siddhartha Mitra, Weifan Ye, Anas Younes, Alison J. Moskowitz

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Identification of a Brainstem Circuit Controlling Feeding

    Identification of a Brainstem Circuit Controlling Feeding 由 Alexander R. Nectow, Marc Schneeberger, Hongxing Zhang, Bianca C. Field, Nicolas Renier, Estefania P. Azevedo, Bindiben Patel, Yupu Liang, Siddhartha Mitra, Marc Tessier‐Lavigne, Ming‐Hu Han, Jeffrey M. Friedman

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

    Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059 由 Harriet S. Walter, Sandrine Jayne, Simon Rule, Guillaume Cartron, Franck Morschhauser, Salvador Macip, Lionel Karlin, Ceri Jones, Charles Herbaux, Philippe Quittet, Nimish Shah, Claire V. Hutchinson, Chris Fegan, Yingsi Yang, Siddhartha Mitra, Gilles Salles, Martin J.S. Dyer

    出版 2017
    獲取全文 獲取全文
    Carta
    加到收藏夾
    Saved in:
  10. 10
    Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

    Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia 由 Alexey V. Danilov, Charles Herbaux, Harriet S. Walter, Peter Hillmen, Simon Rule, Ebenezer A. Kio, Lionel Karlin, Martin J.S. Dyer, Siddhartha Mitra, Ping Yi, Rita Humeniuk, Xi Huang, Ziqian Zhou, Pankaj Bhargava, Juliane M. Jürgensmeier, Chris Fegan

    出版 2020
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    An in vitro pharmacogenomic approach reveals subtype-specific therapeutic vulnerabilities in atypical teratoid/rhabdoid tumors (AT/RT)

    An in vitro pharmacogenomic approach reveals subtype-specific therapeutic vulnerabilities in atypical teratoid/rhabdoid tumors (AT/RT) 由 David Pauck, Daniel Picard, Mara Maue, Kübra Taban, Viktoria Marquardt, Lena Blümel, Jasmin Bartl, Nan Qin, Nadezhda Kubon, Dominik Schöndorf, Frauke-Dorothee Meyer, Johanna Theruvath, Siddhartha Mitra, Martin Hasselblatt, Michael C. Frühwald, Guido Reifenberger, Marc Remke

    出版 2025
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Disease-Associated Polyglutamine Stretches in Monomeric Huntingtin Adopt a Compact Structure

    Disease-Associated Polyglutamine Stretches in Monomeric Huntingtin Adopt a Compact Structure 由 Clare Peters‐Libeu, Jason Miller, Earl Rutenber, Yvonne M. Newhouse, Preethi Krishnan, Kenneth Cheung, Danny M. Hatters, Elizabeth D. Brooks, Kartika Widjaja, Tina Tran, Siddhartha Mitra, Montserrat Arrasate, Luis A. Mosquera, Dean P. Taylor, Karl H. Weisgraber, Steven Finkbeiner

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

    A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia 由 Susan O’Brien, Nicole Lamanna, Thomas J. Kipps, Ian W. Flinn, Andrew D. Zelenetz, Jan A. Burger, Michael J. Keating, Siddhartha Mitra, Leanne Holes, Albert S. Yu, David M. Johnson, Langdon L. Miller, Yeonhee Kim, Roger Dansey, Ronald L. Dubowy, Steven Coutré

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

    Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia 由 Jeff P. Sharman, Steven Coutré, Richard R. Furman, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Eugen Tausch, Paula Cramer, Julie Huang, Siddhartha Mitra, Michael Hallek, Susan O’Brien, Stephan Stilgenbauer

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Identifying polyglutamine protein species in situ that best predict neurodegeneration

    Identifying polyglutamine protein species in situ that best predict neurodegeneration 由 Jason Miller, Montserrat Arrasate, Elizabeth D. Brooks, Clare Peters Libeu, Justin Legleiter, Danny M. Hatters, Jessica Curtis, Kenneth Cheung, Preethi Krishnan, Siddhartha Mitra, Kartika Widjaja, Benjamin A. Shaby, Gregor P. Lotz, Yvonne M. Newhouse, Emily J Mitchell, Alex Osmand, Michelle Gray, Vanitha Thulasiramin, Frédéric Saudou, Mark R. Segal, X. William Yang, Eliezer Masliah, Leslie M. Thompson, Paul J. Muchowski, Karl H. Weisgraber, Steven Finkbeiner

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: